Patrick John Finn Sells 229 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 229 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $45.59, for a total value of $10,440.11. Following the completion of the sale, the chief operating officer now owns 274,466 shares in the company, valued at approximately $12,512,904.94. The trade was a 0.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total value of $496,320.00.
• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total transaction of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total transaction of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The stock was sold at an average price of $43.09, for a total transaction of $97,426.49.

Twist Bioscience Price Performance

Shares of TWST opened at $45.12 on Thursday. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The company has a market capitalization of $2.68 billion, a P/E ratio of -12.53 and a beta of 1.85. The firm’s 50 day simple moving average is $46.26 and its 200 day simple moving average is $46.47.

Institutional Trading of Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB purchased a new position in Twist Bioscience in the third quarter worth $34,000. Signaturefd LLC grew its holdings in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Twist Bioscience in the 2nd quarter worth $61,000. Beaird Harris Wealth Management LLC bought a new stake in Twist Bioscience in the third quarter worth $95,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after buying an additional 381 shares during the period.

Wall Street Analyst Weigh In

TWST has been the subject of a number of analyst reports. Evercore ISI raised their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird raised their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 19th. Wolfe Research assumed coverage on Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. Barclays lowered their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. Finally, TD Cowen reaffirmed a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $51.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.